Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A study of the QuXie capsul in the treatment of advanced colorectal cancer

ABSTRACT: Interventions: treatment group:Qu Xie Jiao Nang+conventional treatment;control groups:conventional treatment Primary outcome(s): immune function Study Design: Randomized parallel controlled trial

DISEASE(S): The Advanced Colorectal Cancer

PROVIDER: 2665422 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Gene expression changes in cecum mucosa upon dietary treatment

Project description:To increase our knowledge of the effects of Fructo oligosaccharides (FOS) on the intestinal barrier function in rats, a controlled rat infection study was performed. Two groups of rats (n=12 per group) were adapted to a diet with or without FOS. mRNA was collected from the mucosa of the cecum and changes in gene expression were assessed using an agilent rat whole genome microarray (G4131A Agilent Technologies). Results indicate that dietary FOS influences immune response and wound healing mechanisms, which will most likely affect the intestinal barrier. Keywords: Dietary treatment, cecum mucosa, Rat

2007-12-31 | GSE8587 | GEO

Study about immune nutritional therapy accerlerated rehabilitation after colorectal cancer surgery in the Fast Track model

Project description:Interventions: Group A:Use the conventional enteral nutrition;Group B:Use the immune enhanced enteral nutrition Primary outcome(s): Nutrition Indicators;immune indexes;The acute phase inflammatory reaction index;Barrier function;FT process postoperative rehabilitation index;The safety index FT proces Study Design: Randomized parallel controlled trial

| 2673775 | ecrin-mdr-crc

Investigation of the association of SNP rs2072183 in NPC1L1 gene and LDL-C reduction induced by hyzetimibe treatment.

Project description:An investigation into the association of SNP rs2072183 in NPC1L1 gene and LDL-C reduction induced by hyzetimibe treatment in a multicenter, randomized, double-blind, balanced-parallel placebo-controlled group study

2021-12-08 | PRJEB49213 | EVA

Colonic gene expression upon dietary treatment

Project description:To increase our knowledge of the effects of Fructo oligosaccharides (FOS) on the intestinal barrier function in rats, a controlled rat infection study was performed. Two groups of rats were adapted to a diet with or without FOS. mRNA was collected from the mucosa of the colon and changes in gene expression were assessed using an agilent rat whole genome microarray (G4131A Agilent Technologies). Results indicate that dietary FOS influences energy metabolism, which will most likely play a role in the effects of FOS on the intestinal barrier. Keywords: Dietary treatment, colon mucosa, Rat

2007-12-01 | GSE5943 | GEO

Effectof postoperative Bifidobacterium lactis M8 on intestinal flora andimmune function in patients with colorectal cancer

Project description:Interventions: Probiotics Group:Bifidobacterium lactis M8;2:Intestinal antimicrobials Primary outcome(s): Intestinal flora;Intestinal barrier function;Humoral immune function;cellular immune function Study Design: Randomized parallel controlled trial

| 2678440 | ecrin-mdr-crc

Single-Cell Analysis Reveals Cellular Reprogramming in Advanced Colon Cancer Following FOLFOX-Bevacizumab Treatment

Project description:The combination of FOLFOX and bevacizumab (FOLFOX-Bev) is a promising treatment for advanced colorectal cancer (CRC). To gain insights into the cellular changes associated with FOLFOX-Bev treatment, we conducted single-cell transcriptomic analysis of CRC samples derived from a patient before and after treatment. Our results show that cancer cells with high proliferative, metastatic, and pro-angiogenic properties respond better to FOLFOX-Bev treatment. Moreover, FOLFOX-Bev enhances CD8+ T cell cytotoxicity, thereby boosting the anti-tumor immune response. Conversely, FOLFOX-Bev impairs the functionality of tumor-associated macrophages, plasma cells, and cancer-associated fibroblasts, leading to a decrease in VEGFB-mediated angiogenesis. Furthermore, FOLFOX-Bev treatment reset intercellular communication, which could potentially affect the function of non-cancer cells. Our findings provide valuable insights into the molecular mechanisms underlying the response of advanced CRC to FOLFOX-Bev treatment and highlight potential targets for improving the efficacy of this treatment strategy.

2023-07-20 | GSE232525 | GEO

Drinking water treatment plant

Project description:Microbial community in two parallel drinking water treatment processes

| PRJEB19237 | ENA

Effects on expression profile of acute congestive heart failure (ACHF) patients monocytes by treatment with conventional drugs.

Project description:Several studies have shown the importance of immune and inflammatory mediators in the pathogenesis of heart failure. In clinical practice has been observed that many conventional drugs can modulate circulating levels of these mediators. Despite, there is poor understanding of the precise mechanisms of these drugs in regulating immune and inflammatory systems. Blood monocytes were isolated from 6 hospitalized patients in Intensive Cardiology Care Unit (ICCU) with symptomatic acute congestive heart failure (ACHF) (NYHA Class III-IV) before and after treatment with conventional drugs (ARBs, ACEIs, diuretics, and beta-blockers). Gene expression analysis (n=11) using whole human genome microarray showed that pharmacological treatment abrogate inflammatory activation of monocytes. The inflammatory response network constructed with Ingenuity Pathway Analysis (IPA) indicates the M-bM-^@M-^\TNFR1 signalingM-bM-^@M-^] as the most significantly modulated after pharmacological treatment and the pro-inflammatory cytokine TNF-alpha associated with more than a fifth of genes considered. In this study, we analyzed the expression profiles of 6 biological replicates of blood monocytes from ACHF patients pre- and post-treatment with conventional drugs (ARBs, ACEIs, diuretics, and beta-blockers). All RNAs from pre-treatment monocytes were hybridized against RNAs from post-treatment RNAs. We performed a total of 11 technical replicates.

2013-10-31 | E-GEOD-51888 | biostudies-arrayexpress

Fezakinumab (anti-IL-22) treatment in adults with moderate-to-severe atopic dermatitis

Project description:We conducted a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD unresponsive to conventional topical or systemic treatment. Fezakinumab (ILV-094; anti IL-22 monoclonal antibody) monotherapy was administered for 12 weeks (primary endpoint), and clinical responses were followed until week 20. AD transcriptome significantly improved at week 12 in fezakinumab vs. placebo (p<1E-18).

2018-09-17 | GSE99802 | GEO

Follow-up of a randomized, double-blind, controlled clinical study on reducing postoperative recurrence and metastasis of colorectal cancer with Quxie Capsule

Project description:Interventions: The treatment group:Conventional treatment add Quxie capsule;The control group:Quxie capsule was not added to conventional treatment Primary outcome(s): Survival index, 5,10,15 year survival;Factors influencing patient survival rate and disease recurrence and metastasis rate (combined disease, KPS score) Study Design: Parallel

| 2699222 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data